To read the full story, subscribe or sign in.

Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets

Oct. 5, 2020

HONG KONG – Xi’an, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets.

BioWorld Deals and M&A Cancer CAR T China

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for April 19.

Somalogic to merge with CM Life Sciences II SPAC, as trendy IPO path continues

BioWorld MedTech

Somalogic Inc. has agreed to go public via a merger with blank-check company CM Life Sciences II. Upon closing, CMLS II – a special purpose acquisition company...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for April 19.

Global cases rise, but more weapons advance to combat COVID-19

BioWorld

As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S.